Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eisai To Reinforce Oncology R&D, Sales To Achieve 17% Income Rise

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Quadrupling profits in the business year from the preceding year and forecasting a solid 17.5 percent rise in the current year, Eisai Co., the fourth-largest Japanese pharma and the only one reporting profit among the four, said it will further reinforce its oncology drug development and sales while accelerating global distribution of Alzheimer's treatment Aricept

You may also be interested in...



Aloxi GMP Problems May Trigger Import Controls

France's Pierre Fabre Medicament Production could find the antiemetic it manufactures for Eisai is barred from the U.S. until it takes corrective action on manufacturing problems.

Aloxi GMP Problems May Trigger Import Controls

France's Pierre Fabre Medicament Production could find the antiemetic it manufactures for Eisai is barred from the U.S. until it takes corrective action on manufacturing problems.

Eisai Signs Bendamustine Deal With Symbio In Singapore And Korea, Highlighting Asian Oncology Market Potential

Tokyo-based biotech start-up Symbio will grant exclusive development and marketing rights for non-Hodgkin's lymphoma drug bendamustine to Japan's fourth-largest drug maker Eisai in both Korea and Singapore

Related Content

UsernamePublicRestriction

Register

SC071632

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel